Overview

Medical transition means using drugs and surgery to make a person's body look more like that of the opposite sex. In practice it can include puberty blockers for adolescents, cross-sex hormones (testosterone for females, estrogen plus testosterone blockers for males) and a range of surgeries that remove or reshape breasts, genitals and reproductive organs. None of these interventions changes a person's sex. They change appearance and hormone levels, and several of them permanently end fertility or alter sexual function.

This hub explains how the medical pathway usually works, how it differs for adolescents and adults, what each intervention does, and why almost every step of it is now disputed. It brings together the pages in this section. Each one covers a single intervention or controversy in depth, with sources and first-hand accounts. Detransitioners are central here because they are the patients the pathway was not designed for. They live with its results, and they are mostly missing from the research that is used to defend it.

The medical pathway

Medical transition is usually described as a sequence of steps. Each step makes the next one more likely. Detransitioners often describe it as a conveyor belt more than a set of separate choices.

1. Social transition: a new name, pronouns and clothing. This is not medical, but it is often where the pathway starts (see social transition).
2. Puberty blockers (adolescents only): GnRH agonists that suppress the body's own sex hormones.
3. Cross-sex hormones: testosterone for females; estrogen with an anti-androgen (spironolactone, cyproterone acetate or a GnRH agonist) for males.
4. Surgery: usually chest surgery first for females. Later steps can include hysterectomy (removal of the womb), oophorectomy (removal of the ovaries), phalloplasty or metoidioplasty (building a penis-like organ from donor tissue or the testosterone-enlarged clitoris) for females, and orchiectomy (removal of the testes), vaginoplasty (building a vagina-like cavity, usually from penile tissue), facial feminisation or breast augmentation for males.

Hormones are usually taken for life, and that is certain once the gonads have been removed. Each surgery also brings its own follow-up care, revisions and complications.

Adolescents: from the Dutch protocol to restriction

The model for treating minors comes from the Netherlands. In the Dutch protocol, gender-dysphoric adolescents could be eligible for puberty suppression at 12, cross-sex hormones at 16 and surgery at 18, after a thorough assessment (de Vries & Cohen-Kettenis 2012). Blockers were presented as a "pause button" that would buy time to think.

The data show that the pause rarely ends in a stop. In a Norwegian national cohort of 1,258 referred young people, 97% of those who started blockers went on to cross-sex hormones (Nyquist et al. 2025, retracted 2026). A pharmacology review reported a similar figure of over 95% (Jorgensen 2022). Critics argue that blockers may lock in an identity that would otherwise have resolved, and that following them straight with hormones in early puberty leaves the child infertile (see puberty blockers and fertility).

The Standards of Care version 8 (SOC8, 2022) from the World Professional Association for Transgender Health (WPATH), the main international professional body for transgender medicine, dropped specific minimum ages for treatment and leaves the timing to individual clinical judgement (Coleman et al. 2022; BMJ 2022). At the same time, several national health systems moved the other way after their own evidence reviews. England now allows blockers only in research. Sweden and Finland restrict hormones to exceptional cases and put psychological care first. Other countries have paused or restricted treatment for minors. These shifts are covered in evidence reviews.

Adults: gatekept versus informed-consent models

Adults usually reach hormones by one of two routes:

• Gatekept (assessment) model: a diagnosis of gender dysphoria and a mental-health assessment, often by a specialist gender clinic, before hormones or surgery are prescribed. This was the older WPATH approach. Some public systems still use it, and their waiting lists can run for years.
• Informed-consent model: hormones are prescribed after the patient signs a consent form. A mental-health assessment or diagnosis is not required. Clinics in the US and Australia offer care this way (Gender Clinic News), as do many telehealth services.

Trans-identified people mostly experience gatekeeping as humiliating and slow. Many detransitioners say the opposite problem harmed them, describing prescriptions after one or two short appointments. The informed consent critique page covers this in detail. People who cannot get hormones through either route sometimes turn to unregulated DIY hormones, which carry no monitoring at all.

Interventions at a glance

The hormones and surgery hubs cover each procedure in more detail. They also cover what happens after stopping testosterone or stopping estrogen.

How this section is organised

Known risks

The table summarises the main documented risks across the pathway. Each linked page has the full risk table for its intervention.

Unknowns. No randomised trials exist, and long-term follow-up is short and incomplete. Key questions have no reliable answers. These include lifetime cardiovascular and cancer risk on cross-sex hormones, how the adolescent brain develops on blockers, what happens to the bones of people who never go through their own puberty, how often fertility recovers, and how many people later regret or reverse treatment. Uncertainty is not the same as safety. It is a risk patients need to be told about.

The state of the evidence

The evidence reviews page covers the Cass Review and the national systematic reviews in detail. In brief:

• The most rigorous recent meta-analyses found very low certainty evidence for every outcome measured after blockers (Miroshnychenko et al. 2025) and low to very low certainty for cross-sex hormones in people under 26 (Miroshnychenko et al. 2025).
• The Cass Review called the evidence base "remarkably weak". Most adult gender clinics in England initially refused to share outcome data for its follow-up study.
• Defenders of the affirmation model argue that randomised trials would be unethical and that the reviews set an impossible bar. Critics reply that low-certainty evidence for permanent interventions in children is exactly what should prompt caution (Block 2023).

Scandals and whistleblowers

The reviews above examined published evidence. A separate set of events (whistleblower disclosures, leaked documents, unpublished studies and regulatory findings) shows how institutions handled that evidence. See gender medicine scandals and whistleblowers, including pages on WPATH, the Endocrine Society, the Tavistock clinic's Gender Identity Development Service (GIDS) (England's former national youth gender clinic) and the American Academy of Pediatrics.

The contested questions

"Transition or suicide"

Parents are often told that a child who is refused transition is at high risk of suicide. Register and clinic data on actual deaths give a far more sober picture than self-report surveys. In a Finnish national cohort of 2,083 young people referred to gender services, the excess suicide risk was no longer statistically significant once specialist psychiatric treatment was taken into account (Ruuska et al. 2024). See suicide and transition for the full evidence and for why this narrative itself may be harmful.

Informed consent

Consent to treatment requires understanding the benefits, risks, alternatives and uncertainties. In a survey of 100 detransitioners, 55% felt their evaluation before transition had been inadequate (Littman 2021). Some argue that true consent is impossible when the risks are unknown even to clinicians, or when the patient is a child who cannot yet weigh lost fertility or sexual function (Gorin 2024). See informed consent critique.

Long-term health and iatrogenic harm

Iatrogenic harm means harm caused by treatment itself. Critics argue that gender medicine has the classic conditions for it: weak evidence, a strong belief in benefit, and little follow-up of people who leave care (Jorgensen 2023). See iatrogenic harm.

Fertility and sexual function

These are the losses young patients are least able to imagine and adults most often grieve. A teenager who says they never want children, or who has never had a sexual relationship, cannot know what they are giving up. See fertility and sexual function.

Detransition data gaps

The "under 1% regret" figure comes mainly from short studies with heavy loss to follow-up (Cohn 2023). Better data suggest discontinuation is not rare. In US military health records, about 30% of people who started hormones had stopped within four years, more often among females (Roberts et al. 2022). Stopping hormones is not always detransition, but few clinics track the difference. In Littman's survey only 24% of detransitioners had told the clinicians who treated them (Littman 2021). In a 2024 survey of 78 young adults who had stopped identifying as transgender, 68% had taken at least one medical step and 91% were female. Participants most often said they had confused mental-health problems or trauma reactions with gender dysphoria (Littman, O'Malley, Kerschner & Bailey 2024).

I never reached out to original clinic and they never followed up after I stopped going so I highly doubt I'm included in any follow up studies, statistics or any of that. —chachidubss, detrans female

Medical pathways in r/detrans stories

detrans.ai has analysed about 3,094 detransition and desistance stories from /r/detrans (detrans.ai stats). An AI assembles each user's posts into a single story. Each story is then scored against about 100 statements, and a statement counts as true only when the model is at least 80% confident. This is a large but self-selected sample of people who post on r/detrans, and AI extraction can make errors. The percentages describe these stories. They are not detransition rates, and they do not describe everyone who transitions.

These stories suggest that many who post on r/detrans had medicalised before they turned back. About seven in ten describe taking hormones, and roughly one in five describe chest surgery. Detransition here is often a medical event with lasting effects, not just a change of label. About a third of stories describe medical complications, and a similar share describe irreversible changes. Because the model only counts a feature when it is mentioned clearly, these are probably underestimates. After detransition, 70% of stories describe a somewhat or much better quality of life and 11% a worse one (detrans.ai stats).

What detransitioners report

These accounts come from /r/detrans and describe individual experiences. They are not a representative sample, but recurring themes show where the pathway fails.

"It wasn't enough": escalation

A common pattern in these accounts is escalation. Each step brings relief for a while, then the distress returns and the next intervention looks like the answer.

Cutting my hair and dressing masculine, hiding my breasts was nice but it wasn't enough. Hormones made my voice deeper and my face more masculine but it wasn't enough. Top surgery made my silhouette masculine but it wasn't enough. It was at that point that I realized nothing would ever be enough because I would always be me and I would always be female. All of these stages left me with permanent health problems. —beanndog, detrans female

This fits the view that, for some people, gender distress is a symptom of something else, such as trauma, mental-health problems, internalised homophobia or internalised misogyny. Medical steps can treat the symptom without touching the cause.

Young age and adult regret

Many of the most painful accounts come from people who began as minors.

puberty blockers and testosterone at 14/15 and top surgery for my 16th bday were the biggest mistakes i've made and let my parents sign off on. —bearspiracy, detrans female

I hold so much resentment towards my doctors, family and friends who let me do this to myself. I was 16 FFS! Now that im 22, it's so easy to see how immature 16 year olds are. —Aware-Resist-8655, detrans male

Consent that wasn't informed

Accounts of informed-consent prescribing describe appointments of minutes, not months, and a diagnosis that came with its treatment already decided.

Two 30 minute appointments and a physical and BAM I'm on HRT. I think some form of therapy (more than 2 sessions) exploring c-ptsd, anxiety, depression, and self esteem issues would have helped. —Lisa_Sae, detrans male

They literally diagnosed me with gender dysphoria and told me what the treatment was for it. Then I "consented" to the treatment... that they told me was the treatment. —brightescala, detrans female

Even patients who were warned about the visible changes say the long-term risks were unknown to the people treating them:

No one can have informed consent because even the professionals are not fully informed on what HRT does to their patient. —watching_snowman, Socially Trans - Regrets entire Transition

Bodily harm and being an experiment

I was left with permanent breast pain. That was not in any of the warnings or medical literature. No one knows what to do with me now. I'm basically the result of a medical experiment I didn't know was an experiment when I participated. —UniquelyDefined, detrans male

One commenter explained why transition regret can cut deeper than ordinary cosmetic-surgery regret:

Plastic surgery generally does not result in sterility, endocrine disruption, or loss of sexual function. Transition often does. Additionally, plastic surgery does not claim to treat a medical problem or present itself as "lifesaving". —writteno, detrans female

Medicalising non-conformity

A broader critique runs through these communities: that medical transition turns ordinary gender non-conformity, same-sex attraction and adolescent body discomfort into a medical condition.

I think we have the same self image issues queers had in the past, but instead of just living with our bodies, we seek medicalization to "fix" us as we've been conditioned to think there's something wrong with us. —furbysaysburnthings, detrans female

All gender nonconformity is being funneled through trans ideology. People who otherwise would not have seen themselves this way are now needing drugs and worsening dysphoria. —eyesclouds, desisted male

The alternative these commenters describe is not a different identity label. It is acceptance of the sexed body together with freedom from stereotypes (see gender non-conformity without labels).

Abandonment after harm

People who detransition often find no clinical pathway for coming off hormones, managing life without gonads or repairing surgical damage.

My endocrinologist couldn't get rid of me fast enough. There is absolutely no detrans healthcare, I am still suffering and my doctors have no clue what to do. —neongrayjoy, detrans female

The support directory lists gender-exploratory therapists and detransition peer groups, and healing and recovery covers life afterwards.

Trans perspectives

Many trans-identified people describe medical transition as the best decision of their lives. Their accounts deserve to be taken seriously.

I celebrate 10 years on HRT tomorrow, and my quality of life is so much better in general, period. I haven't thought about harming myself since starting HRT, and honestly, I haven't looked back. —presentingmaddi, trans woman (MTF)

Taking testosterone for the first time cracked my world open. —Specialist-Bell-1392, trans man (FTM)

Trans commenters generally see gatekeeping, not prescribing, as the main problem. They describe years-long waits and assessments that feel like hazing, and some defend DIY hormones as the only option. Some also play down the risks:

ANY medication taken over prolonged periods has some level of risk, many have risks involved even when taken short term. —Fuzzy-Moose7996, trans woman (MTF)

Detransitioners and trans people often describe the same system from opposite ends. One side sees fast access as liberation, and the other sees it as the moment care failed. Both experiences can be real. Self-reported satisfaction, however, is not the same as evidence of long-term benefit, and the people for whom treatment did not work are the ones the research most often loses. Reasonable people can disagree about adults' freedom to modify their bodies. The case against giving permanent interventions to adolescents on very low-certainty evidence is much harder to answer. The real harm comes from permanent interventions done without fully informed consent.

Further reading

• Detransition and transition regret
• Gender exploratory therapy, a non-medical approach to gender distress
• Gender dysphoria: the diagnosis and its history
• The study archive, detransition videos and statistics

References

• Miroshnychenko, A. et al. (2025). Puberty blockers for gender dysphoria in youth: A systematic review and meta-analysis. Archives of Disease in Childhood. study page, source.
• Miroshnychenko, A. et al. (2025). Gender affirming hormone therapy for individuals with gender dysphoria aged <26 years: a systematic review and meta-analysis. Archives of Disease in Childhood. study page, source.
• Cass, H. (2024). Independent review of gender identity services for children and young people: Final report. study page.
• Block, J. (2023). Gender dysphoria in young people is rising—and so is professional disagreement. The BMJ. study page, source.
• Nyquist, C. B. et al. (2025). Treatment trajectories among children and adolescents referred to the Norwegian National Center for Gender Incongruence. Acta Paediatrica. study page, source.
• Jorgensen, S. (2022). Puberty blockers for gender dysphoric youth: A lack of sound science. JACCP. source.
• Jorgensen, S. C. J. (2023). Iatrogenic Harm in Gender Medicine. Journal of Sex & Marital Therapy. study page, source.
• de Vries, A. L. C. & Cohen-Kettenis, P. T. (2012). Clinical management of gender dysphoria in children and adolescents: the Dutch approach (Treatment of Adolescents With Gender Dysphoria in the Netherlands). source.
• Coleman, E., Radix, A. E., Bouman, W. P., et al. (2022). Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. International Journal of Transgender Health 23(sup1):S1-S259. source.
• BMJ news (2022). US transgender health guidelines leave age of treatment initiation open to clinical judgment. BMJ 378:o2303. source.
• Pertot, S. Standard variation. Gender Clinic News. source.
• Littman, L. (2021). Individuals Treated for Gender Dysphoria with Medical and/or Surgical Transition Who Subsequently Detransitioned: A Survey of 100 Detransitioners. Archives of Sexual Behavior. study page, source.
• Littman, L., O'Malley, S., Kerschner, H. & Bailey, J. M. (2024). Detransition and Desistance Among Previously Trans-Identified Young Adults. Archives of Sexual Behavior. study page, source.
• Gorin, M. (2024). The Aims of Medicine in Pediatric Gender Care: Against the Autonomy-Based View. Hastings Center Report. study page, source.
• Cohn, J. (2023). The Detransition Rate Is Unknown. Archives of Sexual Behavior. study page, source.
• Roberts, C. M. et al. (2022). Continuation of Gender-affirming Hormones Among Transgender Adolescents and Adults. Journal of Clinical Endocrinology & Metabolism. study page, source.
• US Food and Drug Administration (2022). Pseudotumor cerebri warning for GnRH agonists, as reported by the Pediatric Endocrine Society. source.
• European Medicines Agency, PRAC (2020). Cyproterone Article 31 referral: assessment report (EMA/134740/2020). source.
• Getahun, D. et al. (2018). Stroke and Blood Clot Risk in Transgender Women Taking Hormones. PCORI.
• Madsen, M. C. et al. (2021). Erythrocytosis in a Large Cohort of Trans Men Using Testosterone. J Clin Endocrinol Metab. source.
• Zwickl, S. et al. (2023). Pelvic Pain in Transgender People Using Testosterone Therapy. LGBT Health. source.
• Wang et al. (2022). Outcomes Following Gender Affirming Phalloplasty: A Systematic Review and Meta-Analysis. Sexual Medicine Reviews. source.
• Ruuska et al. (2024). All-cause and suicide mortalities among adolescents and young adults who contacted specialised gender identity services in Finland in 1996–2019. BMJ Mental Health. summary.
• detrans.ai (2026). Detransition statistics from /r/detrans stories. stats page.